Overview

Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC

Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the role of everolimus in combination with local Transcatheter Arterial Chemoembolization (TACE) procedure in patients with localized unresectable Hepatocellular Carcinoma (HCC).
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Everolimus
Sirolimus